headline-text-20005

Nov 24, 2000

Ge12 17 99 small

body-text-20005

Biodistribution of Lu-177 AKIR001. (A) Mice (N = 12) bearing BxPC3 tumors were injected with Lu-177 AKIR001 and dissected at 24 (N = 4), 96 (N = 4), and 168 hours (N = 4) postinjection. Error bars represent SD. (B) Representative SPECT/CT images at 96 hours postinjection. GI = gastrointestinal.

SNMMI highlights new radiopharmaceutical therapy

May 13, 2026

Molecular Imaging News Platform: trends, insights, professional views.

Molecular Imaging News Platform: trends, insights, professional views.

April 14, 2026

C-Ray Therapeutics wins FDA active status for Cu-64 drug master file

April 28, 2026

A Rk Nx1 Fop15 Je H Jffj8rq D13

TAG1, NRG Pallas to advance Pb-212 supply for cancer therapies

April 22, 2026

SNMMI highlights new radiopharmaceutical therapy

By AuntMinnie.com staff writers

Mice bearing PDAC xenografts received lutetium-177 (Lu-177) AKIR001, a radiopharmaceutical that targets CD44v6.

May 13, 2026

Biodistribution of Lu-177 AKIR001. (A) Mice (N = 12) bearing BxPC3 tumors were injected with Lu-177 AKIR001 and dissected at 24 (N = 4), 96 (N = 4), and 168 hours (N = 4) postinjection. Error bars represent SD. (B) Representative SPECT/CT images at 96 hours postinjection. GI = gastrointestinal.

Eden Radioisotopes files NRC permit for isotope production complex

By AuntMinnie.com staff writers

The company said the facility is designed to produce up to 50% of global demand for molybdenum-99 (Mo-99).

May 6, 2026

C-Ray Therapeutics wins FDA active status for Cu-64 drug master file

By AuntMinnie.com staff writers

C-Ray Therapeutics has received active status from the FDA for its Type II Drug Master File for Cu-64 chloride for radiolabeling.

April 28, 2026

TAG1, NRG Pallas to advance Pb-212 supply for cancer therapies

By AuntMinnie.com staff writers

TAG1 and NRG Pallas aim to develop access to lead-212 (Pb-212) for cancer drug development across Europe.

April 22, 2026

A Rk Nx1 Fop15 Je H Jffj8rq D13

Ionetix raises $30M to scale radioisotope production

By AuntMinnie.com staff writers

The funding will support scaling up of radioisotope production as well as R&D efforts in nuclear energy, materials testing, and related areas.

April 21, 2026

Telix doses first patient in glioblastoma trial

By AuntMinnie.com staff writers

The patient was dosed at Austin Health in Melbourne, Australia.

April 15, 2026

Shine receives $263M conditional loan for Mo-99 isotope facility

By AuntMinnie.com staff writers

Shine has received a conditional loan from the U.S. DOE to complete the Chrysalis medical isotope production facility for Mo-99.

April 9, 2026

Chrysalis, Shine’s large-scale irradiation facility, will complement the existing supply chain with the goal of ensuring a sustainable and reliable source of isotopes, including Mo-99.

First patients treated in RYZ401 radiopharmaceutical trial

By AuntMinnie.com staff writers

RYZ401 is an investigational actinium-225 (AC-225)-based radiopharmaceutical targeting somatostatin receptors in neuroendocrine tumors.

April 8, 2026

Consortium launches 5-year plan to improve theranostics outcomes

The project aims to pave the way for personalized radiopharmaceutical therapy.

April 6, 2026

SpectronRx raises $85M to expand radiopharmaceutical production

By AuntMinnie.com staff writers

The funding will support infrastructure investment at the company's Grissom Aeroplex campus in Indiana.

April 2, 2026

Cardinal Health expands Ac-225 production

By AuntMinnie.com staff writers

Since launching routine Ac-225 production at scale in late 2024, the company said it has quadrupled its weekly output.

April 1, 2026

Radiopharmaceutical Therapy Tracker

With so many targeted diagnostic and therapeutic radiopharmaceuticals in development for cancer care, AuntMinnie's new pipeline update tool can help keep track.

March 30, 2026

Page 1 of 442